Buy Recommendation for Anavex Life Sciences: Promising Alzheimer's Treatment and Expanding Clinical Pipeline
Anavex Submits Marketing Authorization Application to EU Regulator for Blarcamesine to Treat Alzheimer's; Shares Jump Pre-Bell
Express News | Anavex Life Sciences Announces Submission of Blarcamesine Maa for Treatment of Alzheimer’s Disease to EMA
Anavex Life Sciences Is Maintained at Buy by D. Boral Capital
Anavex Life Sciences Price Target Maintained With a $46.00/Share by D. Boral Capital
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal
